- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01804218
Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Anticipé)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Missouri
-
St. Louis, Missouri, États-Unis, 63110
- Washington University School of Medicine
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27704
- Duke University Medical Center
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Baylor College of Medicine
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Individuals who meet all of the following criteria are eligible for enrollment as study participants:
1. Males and females with physician-diagnosed asthma between the ages of 18- 60.
2. Pre-bronchodilator FEV1 80% or greater than the predicted value
3. Baseline PC20 (based on FEV1) ≤ 4 mg/ml on methacholine challenge test.
4. Asthma Control Questionnaire Score (ACQ) <1.25
5. Baseline blood pressure ≥ 110/65mm Hg
6. Baseline pulse rate ≥ 60 beats/min.
7. Never-smoker or former-smoker < 10 pack.year and has not smoked within 1 year.
8. Able to complete diary cards and comply with study procedures.
9. Females of childbearing age may participate only if they have a negative pregnancy test, are non-lactating, and agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study.
Exclusion Criteria:
Subjects who meet ANY of the following criteria are not eligible for enrollment:
- Inability or unwillingness of the participant to give written informed consent
- History of upper/lower respiratory tract infection or asthma exacerbation requiring systemic steroids within 6 weeks of Visit 1
- Use of rescue medication (e.g., albuterol) more than twice per week during the week preceding Visit 1 excluding the use of such medication as preventative prior to exercise.
- History of hospitalization for asthma in the preceding year
- History of intubation for asthma
- Currently diagnosed with chronic obstructive pulmonary disease (COPD)
- Currently taking any beta-blocker medication
- History of adverse reaction or allergy to any beta-blocker medication
- History of neurological, hepatic, renal, or other medical conditions that may interfere with the interpretation of data or the patient's participation in the study or may increase safety concerns
- Current diabetes or hyperthyroidism
- History of cardiovascular diseases including uncontrolled hypertension (BP >160/100), ischemic heart disease, congestive heart failure, valvular heart disease or cardiomyopathy
- Known allergy or sensitivity to atropine or ipratropium bromide
- Abnormal entry laboratory values at baseline except for the following tests, where values outside the normal limits will be acceptable as follows: Hct ≥ 30%, platelet count > 100,000, ALT and AST < 1.5 x upper normal limit
- Known bleeding disorders, platelet count <100,000, PT or PTT > 1.5 x normal control (if participating in bronchoscopy sub-study)
- Known allergy to lidocaine (if participating in bronchoscopy sub-study)
- Documented or self-reported current history of alcoholism or drug abuse
- Participation in another research trial within 30 days of starting this trial
- Unwillingness or inability to comply with study procedures
- Inability to swallow the study medication capsule
- Use of any exclusion medication within the time period specified
- Pregnant or nursing
- Receiving allergen immunotherapy (desensitization injections)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
|
|
|
Expérimental: Actif, nadolol
Actif
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
The change in methacholine provocative concentration causing a 20% fall (PC20) based on forced expiratory volume in 1 second (FEV1) between baseline visit and final dose dispensing visit.
Délai: 4 months
|
4 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Nicola A. Hanania, MD, MS, Baylor College of Medicine
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Maladies du système immunitaire
- Maladies pulmonaires
- Hypersensibilité immédiate
- Maladies bronchiques
- Maladies pulmonaires obstructives
- Hypersensibilité respiratoire
- Hypersensibilité
- Asthme
- Effets physiologiques des médicaments
- Bêta-antagonistes adrénergiques
- Antagonistes adrénergiques
- Agents adrénergiques
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Agents anti-arythmie
- Agents antihypertenseurs
- Agents autonomes
- Agents du système nerveux périphérique
- Sympatholytiques
- Nadolol
Autres numéros d'identification d'étude
- U01-BCM-01
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .